摘要
背景:美国国家任务组(NTG)为唐氏综合症患者痴呆筛查(DS)和其他形式的身份(非DS)者提倡改编版的痴呆筛查问卷为智障人士使用(dsqiid)。 目的:为了满足这些准则,研究表明在一个由40岁以上的DS和DS ID非成年人意大利版的心理测量学特性。 方法:内部一致性、跨评估者和评估者内信度、结构效度、会聚效度和已知组差异与招募200个来自意大利市15个中心的老年痴呆患者(ID评估(55.2年;平均范围40-80岁)。老年痴呆症的诊断是根据IASSID诊断标准和临床确定度做的西尔弗曼等人定义的分类(2004)。 结果:克龙巴赫的阿尔法的dsqiid-i 0.94。ICC为评分者间信度和重测信度为0.89。主成分分析显示三个领域,即记忆和混乱相关的项目,运动和功能残疾,抑郁和冷漠,这解释了几乎40%的整体方差。总dsqiid-i评分显著相关,不同个体显著的DMR(n = 34)与认知功能下降无(N = 166)。年龄、性别和身份的dsqiid-i.严重程度无关 结论:本研究证实了,文化的价值dsqiid这是一种心理测量学的有效的和用户友好的观察员的规模与DS和DS ID非成人痴呆筛查。
关键词: 阿尔茨海默病(AD),痴呆,智力残疾,心理测量学,筛查试验,验证。
Current Alzheimer Research
Title:A Multicentre Italian Validation Study in Aging Adults with Down Syndrome and Other Forms of Intellectual Disabilities: Dementia Screening Questionnaire for Individuals with Intellectual Disabilities
Volume: 14 Issue: 7
关键词: 阿尔茨海默病(AD),痴呆,智力残疾,心理测量学,筛查试验,验证。
摘要: Background: The USA National Task Group (NTG) guidelines advocate the use of an adapted version of Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID) for dementia screening of individuals with Down syndrome (DS) and with other forms of ID (non-DS).
Objective: In order to meet these guidelines, this study verifies the psychometric properties of an Italian version of the original DSQIID in a population composed of adults aged 40 years and over with DS and non-DS ID. Methods: Internal consistency, inter-rater and intra-rater reliabilities, structural validity, convergent validity and known group differences of DSQIID-I were assessed with 200 individuals with ID (mean of 55.2 years; range: 40-80 years) recruited from 15 different centers in Italy. Diagnosis of dementia was done according to IASSID diagnostic criteria and its degree of clinical certainty was defined according to Silverman et al.’s classification (2004). Results: Cronbach’s alpha for the DSQIID-I was 0.94. The ICCs for inter-rater and test-retest reliability were both 0.89. A Principal Component analysis revealed three domains, namely memory and confusion- related items, motor and functional disabilities, depression and apathy, which explained almost 40% of the overall variance. The total DSQIID-I score correlated significantly with DMR and differed significantly among those individuals (n = 34) with cognitive decline from those without (n = 166). Age, gender and severity of ID were unrelated to the DSQIID-I. Conclusion: The present study confirms the cross-cultural value of DSQIID which was proved to be a psychometrically valid and user-friendly observer-rated scale for dementia screening in adults with both DS and non-DS ID.Export Options
About this article
Cite this article as:
A Multicentre Italian Validation Study in Aging Adults with Down Syndrome and Other Forms of Intellectual Disabilities: Dementia Screening Questionnaire for Individuals with Intellectual Disabilities, Current Alzheimer Research 2017; 14 (7) . https://dx.doi.org/10.2174/1567205014666170117094757
DOI https://dx.doi.org/10.2174/1567205014666170117094757 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
AβPP-induced UPR Transcriptomic Signature of Glial Cells to Oxidative Stress as an Adaptive Mechanism to Preserve Cell Function and Survival
Current Alzheimer Research Regression to the Mean: Implications for Clinical Trials of Psychotropic Agents in Dementia
Current Alzheimer Research Mediterranean Diet and Dementia of the Alzheimer Type
Current Aging Science Identifying Patterns in Signs and Symptoms Preceding the Clinical Diagnosis of Alzheimer’s Disease: Retrospective Medical Record Review Study and a Nested Case-control Design
Current Alzheimer Research The Role of Adenosine in Alzheimers Disease
Current Neuropharmacology Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Current Vascular Pharmacology Microdose Lithium Treatment Stabilized Cognitive Impairment in Patients with Alzheimer’s Disease
Current Alzheimer Research Mechanisms Involved in BACE Upregulation Associated to Stress
Current Alzheimer Research Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Poly(ADP-Ribose)Polymerase 1 (PARP-1) Activation and Ca<sup>2+</sup> Permeable α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Channels in Post-Ischemic Brain Damage: New Therapeutic Opportunities?
CNS & Neurological Disorders - Drug Targets Computer Simulations of Alzheimers Amyloid β-Protein Folding and Assembly
Current Alzheimer Research Tauopathies – Focus on Changes at the Neurovascular Unit
Current Alzheimer Research Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease
Current Medicinal Chemistry Combination of Memantine and 6-Chlorotacrine as Novel Multi-Target Compound against Alzheimer’s Disease
Current Alzheimer Research The Effect of Cyberspace-Based Education on the Well-Being of Caregivers of Elderly People with Dementia
Current Aging Science The Developing Utility of Zebrafish Models for Cognitive Enhancers Research
Current Neuropharmacology Neuroprotective Effects of Lithium in Patients with Bipolar Disorder
Current Psychopharmacology Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Gene-environment Interactions in Late Life: Linking Psychosocial Stress with Brain Aging
Current Neuropharmacology Flavonoids Protect Cerebrovascular Endothelial Cells through Nrf2 and PI3K from β-Amyloid Peptide-Induced Oxidative Damage
Current Neurovascular Research